Fig. 7
From: ST6GALNAC4 promotes hepatocellular carcinogenesis by inducing abnormal glycosylation
ST6GALNAC4 exerted immunosuppressive effects through the recruitment of Galectin3+TAMs. Proportions of Galectin3+ macrophages in tumor (A) and spleen (B) between shst6galnac4 group and control group on flow cytometry. C Proportions of Galectin3+ macrophages in spleen between shLgals3 AAV infection group and control group on flow cytometry. D Proportions of CD8+ and CD4+ T cell populations between shLgals3 AAV infection group and control group on flow cytometry. E Tumors in orthotopic liver model in C57BL/6 mice between GB1107 treatment and control group in vivo imaging system (IVIS). F Maximum fluorescence curve between GB1107 treatment and control group in vivo imaging system (IVIS). G Tumors volume curve in subcutaneous xenografted model in C57BL/6 mice between shLgals3 group and control group, each line indicates a single mouse. H Tumors weight in cell mixing subcutaneous xenografted model in C57BL/6 mice between shLgals3 group and control group. I Schematic representation of the mechanism for ST6GALNAC4 in HCC